Why Encapsulated Actives Outperform Standard Skincare Formulations

Why Encapsulated Actives Outperform Standard Skincare Formulations

Most skincare products list impressive actives on their ingredient panels. The gap between what is listed and what reaches the skin is where most formulations fall short.

The problem is not always concentration. It is stability and delivery. Vitamin A oxidises rapidly when exposed to air and light. Vitamin C degrades quickly in water-based formulas. Without a protective delivery system, a significant proportion of these actives never reaches the skin layer where they can act.

Encapsulation addresses this by surrounding each active in a protective shell that preserves it until it contacts the skin surface. Once there, the shell breaks down and releases the active in a controlled way over several hours. The result is a sustained dose rather than a one-time hit.

For vitamin A specifically, this matters enormously. Conventional retinol applied at 1% will cause irritation in most people because the skin receives the full concentration immediately. Encapsulated vitamin A at 1% releases slowly across 8 to 12 hours, allowing the same concentration to be used twice daily on sensitive skin without the dryness and peeling that makes conventional retinol difficult to sustain.

The same principle applies to vitamin B3. At 10% encapsulated, the active is delivered progressively rather than flooding the skin at once. This allows a clinically meaningful dose to be used daily without the transient flushing that can occur with high-dose free-form applications.

For anyone serious about results, the delivery system is as important as the concentration. Professional-grade skincare built around encapsulation technology closes the gap between what is on the label and what the skin actually receives. The ABC Serum from Rejuvaus contains 1% encapsulated vitamin A, 10% encapsulated vitamin B3, and 5% vitamin C superfruit extract in a single twice-daily formula.

Encapsulation is not a marketing claim. It is the formulation decision that determines whether an active performs as its published evidence suggests, or sits on the skin surface doing a fraction of the work it is capable of.